Global CNS Therapeutics Market to Reach $285.72 Bn by 2035, Growing at 8.64% CAGR
The global CNS therapeutics market was valued at USD 127.29 billion in 2025 and is projected to reach USD 285.72 billion by 2035, driven by demand for Alzheimer’s and Parkinson’s treatments. North America held 45% of the market; neurodegenerative diseases were the largest segment. Private investment and trends toward biologics and AI are shaping the sector.
The global central nervous system (CNS) therapeutics market was valued at USD 127.29 billion in 2025 and is predicted to reach around USD 285.72 billion by 2035, expanding at a compound annual growth rate (CAGR) of 8.64% from 2026 to 2035. CNS therapeutics includes medications, biologics, and advanced treatment methods targeting the brain and spinal cord. Growing demand for effective therapies for Alzheimer’s disease, Parkinson’s disease, and mental health disorders is further accelerating market expansion, supported by ongoing research, technological breakthroughs, and expanding healthcare infrastructure.
In 2025, North America dominated the global market, accounting for the largest revenue share of 45%. By disease type, the neurodegenerative diseases segment held a leading position, contributing over 40% of the total market share. The CNS cancer segment is expected to register the fastest growth during the forecast period.
Key trends reshaping the market include a significant shift toward disease-modifying biologics, which target underlying biological causes of neurodegenerative conditions rather than merely managing symptoms. The integration of digital therapeutics and artificial intelligence is also accelerating, with AI used to speed drug discovery and digital tools enabling more precise patient monitoring and personalized treatment for chronic conditions like epilepsy and depression.
Recent private industry investments in CNS therapeutics include:
- Isomorphic Labs, a DeepMind spin-off, raised a $600 million seed round from Alphabet and Thrive Capital in early 2025 to use AI for neurodegenerative disease treatments.
- Seaport Therapeutics secured $225 million in Series B funding in late 2024 to advance its neuropsychiatric pipeline using a delivery platform for depression and anxiety medicines.
- Draig Therapeutics emerged from stealth in 2025 with $140 million in Series A backing from Sanofi Ventures to develop neurotransmission-targeting therapies for major depressive disorder.
- GRIN Therapeutics received $140 million in Series D financing, including from Blackstone Life Sciences, to support treatments for rare pediatric neurodevelopmental disorders.
- Ambros Therapeutics raised $125 million in Series A funding led by RA Capital Management to advance therapies for complex regional pain syndromes.
The development of nanocarrier engineering techniques also presents a significant opportunity, enabling nanoscale delivery vehicles that effectively cross the blood-brain barrier and potentially reshape the management of neurological disorders.